Regular "trespasser" cat has some disease
This cat is not mine, just regularly wander through the backyard. I made this video to show it to the local vet to find out what #39;s wrong and cure it, if it is possible. My guess based on relevant youtube videos and some searches is: cerebellar ataxia.From:dtg977Views:13 0ratingsTime:01:46More inPets Animals

Read the original here:
Regular "trespasser" cat has some disease - Video

Leo #39;s Journey. 4 year old affected by Cep290. Joubert Syndrome. Lebers Congenital Amaurosis.
Meet Leo... He is a beautiful, clever, funny little boy. He is also registered blind, has ataxia and kidney problems all related to the Cep290 gene fault. This is his journey so far. See http://www.viskid.com or http://www.facebook.com/VisKidFoundationFrom:Hannah LakeViews:40 0ratingsTime:03:29More inPeople Blogs

Go here to see the original:
Leo's Journey. 4 year old affected by Cep290. Joubert Syndrome. Lebers Congenital Amaurosis. - Video

Leo #39;s Journey. 4 year old affected by Cep290. Joubert Syndrome. Lebers Congenital Amaurosis.
Meet Leo... He is a beautiful, clever, funny little boy. He is also registered blind, has ataxia and kidney problems all related to the Cep290 gene fault. This is his journey so far. See http://www.viskid.com or http://www.facebook.com/VisKidFoundationFrom:Hannah LakeViews:40 0ratingsTime:03:29More inPeople Blogs

Go here to see the original:
Leo's Journey. 4 year old affected by Cep290. Joubert Syndrome. Lebers Congenital Amaurosis. - Video

Jeremy Kyle #39;Inspirational Children #39; episode, Leo, Joubert Syndrome.
This is 4 year old Leo #39;s #39;Inspirational Children #39; episode of Jeremy Kyle, October 2012. Leo is registered blind, has ataxia and kidney problems. He is also extremely cute!!From:Hannah LakeViews:81 1ratingsTime:09:12More inComedy

Visit link:
Jeremy Kyle 'Inspirational Children' episode, Leo, Joubert Syndrome. - Video

Jeremy Kyle #39;Inspirational Children #39; episode, Leo, Joubert Syndrome.
This is 4 year old Leo #39;s #39;Inspirational Children #39; episode of Jeremy Kyle, October 2012. Leo is registered blind, has ataxia and kidney problems. He is also extremely cute!!From:Hannah LakeViews:81 1ratingsTime:09:12More inComedy

Visit link:
Jeremy Kyle 'Inspirational Children' episode, Leo, Joubert Syndrome. - Video

How To Raise Kids Gluten Free
xxsurl.com How To Raise Kids Gluten Free How To Raise Kids Gluten Free ORDER NOW FAQ Disclaimer Privacy About Affiliates Contact Blog Attention: Parents of kids with celiac disease and/or gluten intolerance You Just Found Your DefinitiveGuide To Raising Happy Kids In A Gluten Free World This is an actual practical guide (not a theoretical-medical exposition) on how you can get your kids to survive and thrive despite celiac disease and/or gluten intolerance. ABSOLUTELY EVERYTHING you need to know about raising gluten-free kids from infancy to their teenage years is right here! This was written by a parent, for parents. Thank You Thank You Thank You!! What else can I say! I love your book. It has been so helpful to me but particularly for my child. We can now go out to restaurants I feel like T have got my life back!. We set our kitchen up just like you recommended and now never get any cross contamination. Thanks for that advise. And now I know where to get all the pre-manufacturedgluten-free food. WOW! I never knew there was so much variety until I read this book. Cant thats you enough. Lynn Dawson Dayton, Ohio USA Invaluable book, highly recommended My son was recently diagnosed as Gluten Intolerant, so I bought this book. I found it an invaluable resource and would I strongly recommend it to anyone looking for great advice and helpful hints and recommendations. Not only does it cover the medical aspects of the condition including what medical tests are available, but it ...From:robertroberts9865Views:0 0ratingsTime:01:48More inPeople Blogs

The rest is here:
How To Raise Kids Gluten Free - Video

[2 of 12] Bruteman Live! Concert 2012 (With My Own Eyes)
Part 2 of 12 (With My Own Eyes), video from the 2012 Bruteman Live! Philanthropy Concert for Ataxia Research in London, Ontario, Canada. Proceeds donated to the Canadian Association for Familial Ataxias, http://www.lacaf.org. Staring "Bruteman" Roger Foley, Sarah Smith, Laura Gagnon, Dana Hartman, Kristin Dawn, Pete Comrie, Ken Ross, the Ill At Will dance crew, the Brute Beauties, and more. Concert from October 20th 2012 at London, Ontario #39;s Wolf Performance Hall, concert a part of the Canadian Ataxia Conference lineup of events. http://www.bruteman.com http://www.sarahsmithmusic.com http://www.canadianataxiaconference.com http://www.lacaf.orgFrom:CAFAcentralViews:0 0ratingsTime:07:36More inEntertainment

Go here to see the original:
[2 of 12] Bruteman Live! Concert 2012 (With My Own Eyes) - Video

[1 of 12] Bruteman Live! Concert 2012 (opening stage reveal)
Part 1 of 12, video from the 2012 Bruteman Live! Philanthropy Concert for Ataxia Research in London, Ontario, Canada. Proceeds donated to the Canadian Association for Familial Ataxias, http://www.lacaf.org. Staring "Bruteman" Roger Foley, Sarah Smith, Laura Gagnon, Dana Hartman, Kristin Dawn, Pete Comrie, Ken Ross, the Ill At Will dance crew, the Brute Beauties, and more. Concert from October 20th 2012 at London, Ontario #39;s Wolf Performance Hall, concert a part of the Canadian Ataxia Conference lineup of events. http://www.bruteman.com http://www.sarahsmithmusic.com http://www.canadianataxiaconference.com http://www.lacaf.org mdash; at Wolf Performance Hall, Central Library London, OntarioFrom:CAFAcentralViews:0 0ratingsTime:06:59More inEntertainment

Go here to see the original:
[1 of 12] Bruteman Live! Concert 2012 (opening

[3 of 12] Bruteman Live! Concert 2012 (Foosih Dogs and Diamonds)
Part 3 of 12 (Foolish Dogs are man #39;s best friend but diamonds are a girl #39;s best friend), video from the 2012 Bruteman Live! Philanthropy Concert for Ataxia Research in London, Ontario, Canada. Proceeds donated to the Canadian Association for Familial Ataxias, http://www.lacaf.org. Staring "Bruteman" Roger Foley, Sarah Smith, Laura Gagnon, Dana Hartman, Kristin Dawn, Pete Comrie, Ken Ross, the Ill At Will dance crew, the Brute Beauties, and more. Concert from October 20th 2012 at London, Ontario #39;s Wolf Performance Hall, concert a part of the Canadian Ataxia Conference lineup of events.From:CAFAcentralViews:0 0ratingsTime:04:23More inEntertainment

See the article here:
[3 of 12] Bruteman Live! Concert 2012 (Foosih Dogs and Diamonds) - Video

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Proteostasis Therapeutics, Inc., a company developing novel therapeutics that regulate protein homeostasis to improve outcomes for patients with neurodegenerative and orphan diseases, announced today that company scientists made presentations at two premier scientific conferences. These presentations highlighted progress with the Companys lead programs in cystic fibrosis (CF) and Parkinsons disease (PD) and demonstrated the potential of its differentiated approach to developing disease modifying therapeutics.

At the North American Cystic Fibrosis Conference, we presented data that show how our Proteostasis Network drug discovery platform can identify proteostasis regulators that function as correctors of F508 CFTR, the most common genetic mutation leading to CF. Our data at the Society for Neuroscience Annual Meeting show how the modulation of proteasome activation through the inhibition of Usp14, a deubiquitinase enzyme, stimulates the degradation of -synuclein, a misfolding- and aggregation-prone protein that can accumulate in the brains of PD patients, commented Peter H. Reinhart, Ph.D., President and Chief Scientific Officer of Proteostasis Therapeutics.We are planning to begin clinical trials for both programs in 2014 and are very encouraged by the data we have generated to date.

About Proteostasis Therapeutics

Proteostasis Therapeutics is developing disease-modifying therapeutics for orphan and neurodegenerative diseases. The Companys lead programs in cystic fibrosis (CF) and protein aggregation disorders such as Parkinsons disease (PD) modulate protein chaperone and proteasomal degradation pathways within the cell. These pathways are part of the cellular quality control machinery, called the protein homeostasis network or Proteostasis Network (PN) that regulates protein folding, trafficking, and clearance. By enhancing the function and capacity of the PN, the Companys product candidates correct for imbalances in the PN resulting from the cumulative effects of disease, genetic mutations, environmental factors, and aging. For more information, please visit the Companys website at http://www.proteostasis.com.

Go here to read the rest:
Proteostasis Therapeutics Presents Data at Two Scientific Conferences for Lead Programs in Cystic Fibrosis and ...

25 October 2012 Last updated at 10:43 ET

Campaigners who claim keeping a disabled man in a London prison will shorten his life have staged a protest outside the Ministry of Justice.

Daniel Roque Hall, 30, was jailed in July after admitting trying to smuggle cocaine worth more than 300,000 in his wheelchair from Peru through Heathrow.

He was sent to Wormwood Scrubs, but suffered heart failure within weeks.

The Ministry of Justice said it ensured that all prisoners had the same access to NHS services as everyone else.

An application for a judicial review regarding his case was rejected by a judge at the High Court last week.

Mr Hall who has Friedreich's ataxia, which causes loss of physical co-ordination, remains in hospital.

He has impaired speech, diabetes and a weakened heart, and was being cared for round-the-clock before he was sent to prison.

The judge who sentenced Mr Hall to three-and-a-half years in prison at Isleworth Crown Court asked Wormwood Scrubs for an assurance that it could meet all his medical needs.

The prison said it could.

View original post here:
Prisoner supporters stage protest

Question: I am a 26-year-old black woman. All through high school, I begged my mother to let me get my ears pierced. She said to wait until I graduated from college and was on my own. I did. On each ear, the piercing left a huge scar. The doctor called it a keloid. What are keloids and what is their treatment?

Answer: Keloids are scars that form far too much scar tissue. The result is an unsightly, overgrown and sometimes disfiguring scar. Scars from surgery, from an inadvertent cut and from procedures as innocuous as ear piercing can become keloids. People of Asian and African descent are particularly vulnerable to developing such scars.

I don't want to discourage you, but keloid treatment often involves a recurrence of a keloid scar. Plastic surgeons and dermatologists are the doctors to consult for possible correction.

I'll give you some examples of how keloids are treated:

One way is injecting them with potent cortisone drugs, such as triamcinolone. A good response occurs in 70 percent of patients, but the recurrence rate is also high.

Excision of the scar followed by triamcinolone injections into the newly healing tissues is another method.

Silicone gel sheeting can reduce the size of a keloid. The sheeting is cut to cover the keloid and is taped in place. It's left on the keloid for up to 24 hours, then washed and reapplied. The sheet is replaced about every two weeks.

Freezing the keloid,

Radiation after surgical excision is another way to remove keloids.

Use of a laser in combination with cortisone injections has its proponents.

See the original post here:
To Your Good Health: Keloid is scar that won't stop growing

Question: I am a 26-year-old black woman. All through high school, I begged my mother to let me get my ears pierced. She said to wait until I graduated from college and was on my own. I did. On each ear, the piercing left a huge scar. The doctor called it a keloid. What are keloids and what is their treatment?

Answer: Keloids are scars that form far too much scar tissue. The result is an unsightly, overgrown and sometimes disfiguring scar. Scars from surgery, from an inadvertent cut and from procedures as innocuous as ear piercing can become keloids. People of Asian and African descent are particularly vulnerable to developing such scars.

I don't want to discourage you, but keloid treatment often involves a recurrence of a keloid scar. Plastic surgeons and dermatologists are the doctors to consult for possible correction.

I'll give you some examples of how keloids are treated:

One way is injecting them with potent cortisone drugs, such as triamcinolone. A good response occurs in 70 percent of patients, but the recurrence rate is also high.

Excision of the scar followed by triamcinolone injections into the newly healing tissues is another method.

Silicone gel sheeting can reduce the size of a keloid. The sheeting is cut to cover the keloid and is taped in place. It's left on the keloid for up to 24 hours, then washed and reapplied. The sheet is replaced about every two weeks.

Freezing the keloid,

Radiation after surgical excision is another way to remove keloids.

Use of a laser in combination with cortisone injections has its proponents.

See the original post here:
To Your Good Health: Keloid is scar that won't stop growing

HORSHAM, Pa., Oct. 18, 2012 /PRNewswire/ --A panel of parents who became patient advocates after their children were diagnosed with rare diseases will discuss their struggles and successes in navigating the drug development process on Monday at a Washington, D.C., conference sponsored by DIA and the National Organization for Rare Disorders (NORD).

The work carried out by these parents through rare disease associations can be one of the most important factors in getting lifesaving help for their children. For many parents, the news that their child has a rare disease has changed the course of their lives, including their leaving other careers to work full time to advance the development of therapies to treat severe illnesses that may affect as few as 500 people in the United States. Five of these parents and one patient will speak at the 2012 U.S. Conference on Rare Diseases and Orphan Products.

"People are going along living their lives and then learn their child has a rare disease. These parents are diving into a world unknown to them to navigate the complicated path to find a treatment," said Peter L. Saltonstall, NORD president and CEO. "We see it over and over again. The result can be critical funding and advocacy for groundbreaking research."

Patient advocate Ron Bartek lost his son, Keith, to Friedreich's ataxia, a genetic disease that affects the heart and muscles. There is no treatment for the disease. Bartek and his wife, Raychel, founded the Friedreich's Ataxia Research Alliance, working tirelessly to raise money for research and clinical trials to advance the likelihood of developing an effective treatment.

Bartek said pharmaceutical companies showed no interest in developing a drug for the disease because it is so rare. Fourteen years later, he is confident that clinical trials under way will result in the first treatment for the diseasethanks to the money the alliance raised for research and clinical trials.

"They got interested because we did all of that," said Bartek. "It's almost purely a financial decision. Whether a treatment gets developed often depends on the ability of patients or their advocates to get the process started."

Pharmaceutical companies traditionally have turned their attention to developing therapies for diseases that affect larger patient populations. Because the drug development process is very expensive, time-consuming and challenging, companies have had few incentives to commit the resources to develop therapies that affect very small numbers of patients. However, data show a recent renewed interest by pharmaceutical and biotech companies in the development of rare disease therapies.

Other panelists include:

WHAT:

Panel discussion for members of the media featuring advocates for rare disease patients at the U.S. Conference on Rare Diseases and Orphan Products

More:
Patient Advocates Tell of Struggles in Getting Drugs Developed for Rare Diseases

By PETER BAUMANN/lbedit9@laramieboomerang.com Saturday, October 06, 2012

On her left arm, above two sky blue bracelets, is a scar.

A year and a half after accidentally burning herself, its still there, and it shouldnt be.

For Shawna Hysong, scars, bruises and broken toes linger much longer than they would for the average 21 year-old woman.

The reason is the word on her two bracelets: Ataxia.

I didnt even know it was a word until they told me I had it, Shawna said. I was like, What is that?

Before being diagnosed in 2010 with Ataxia with Oculomotor Apraxia 2 (AOA2), Shawna thought she was merely clumsy. Falling down was common, and in high school she would have to brace herself against a railing or wall to go up stairs.

I thought that everybody kind of had these symptoms but that they covered them up better than I did, she said. I knew something was off when I started feeling not safe going up and down the stairs.

A neurological disorder passed on through genes, AOA2 affects everything. Shawna uses a cane to walk; her vision is bad enough that she cant drive, her hands incapable of holding a pen and writing. As the disorder progresses, it shrinks the part of the brain responsible for motor control.

I would just say that it makes me really clumsy, she said. My cerebellum is shrinking, thats what causes ataxia, this form anyway. There are lots of different forms of ataxia, and they all kind of affect people differently.

See the original post here:
Woman living with ataxia wants to ‘live each day’

FARMINGTON, Conn., Oct. 31, 2012 /PRNewswire-iReach/ -- Learn about the global market for progressive ataxia and weakness disorder treatments and the factors that will influence the long-term development of neurodegenerative disorders in the pharmaceutical and biotechnology markets; learnabout the treatments that are most likely to be commercialized in the next five years.

(Photo: http://photos.prnewswire.com/prnh/20121031/CG03571)

Global Information Inc (GII) is announces the availability of four significant market research reports from our premium research partner BCC Research.

Pharmaceutical biotechnical companies, research institutes and physicians will find these new studies to be of interest.

Global Markets for Treatments for Syndromes of Progressive Ataxia and Weakness Disorders

The global market for treatments for syndromes of progressive ataxia and weakness disorders was valued at nearly $14 billion in 2011 and should reach nearly $15 billion in 2012. Total market value is expected to reach nearly $23.5 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 9.4%.

Key areas of growth in the neurodegenerative disorder market include: Friedreich's ataxia, Gerstmann-Straussler-Scheinker disease, Machado-Joseph disease, amyotrophic lateral sclerosis, progressive bulbar palsy, hereditary spastic paraplegia, hereditary neuropathies and multiple sclerosis.

The report discusses applications for neurodegenerative disorder treatment and therapy technologies, with emphasis on small-molecule and monoclonal antibodies technology. The report also covers significant patents and their allotments in each category.

An Executive Summary for this report and free sample pages from the full document are available at http://www.giiresearch.com/report/bc252617-global-markets-treatments-syndromes-progressive.html

Focus on Progressive Ataxia

See more here:
Global Market for Neurodegenerative Disorder Treatments to Reach $23.5 billion in 2017, Weakness Disorders Treatments ...